David Carcedo

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers

Edurne Arriola, Reyes Bernabé, Rosario García Campelo et al. · JCO Precision Oncology · 2023 · 43 citations · Full text

Medicine, Oncology, Pharmacoeconomics +16

<p>Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD</p>

Marc Miravitlles, Alicia Marín, Alicia Huerta et al. · International Journal of COPD · 2020 · 26 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)

Clara Salas, Javier Martín-López, Antonio Martı́nez et al. · Journal of Clinical Pathology · 2021 · 19 citations · Full text

Medicine, Oncology, Pathology +14

Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective

Enrique de Álava, María Jesús Pareja, David Carcedo et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2022 · 18 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019

Manuel García‐Goñi, Isabel Río-Álvarez, David Carcedo et al. · Pharmaceuticals · 2021 · 17 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +17